All In Biotech

Drug Trial Radar · NCT06050915

A Study of DISC-3405 in Healthy Volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Characteristics of DISC-3405 in Adult Healthy Male and Female Volunteers

Last checked: Nov 19, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Oct 3, 2023

Primary completion

Jul 9, 2024

Study completion Jul 9, 2024

Sponsor

Lead sponsor
Disc Medicine, IncIndustry
Sponsor type
Industry
First posted
Sep 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase 1 study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of DISC-3405 in adult male and female healthy volunteers.

Conditions

  • Healthy Volunteer

Interventions

  • DISC-3405Drug

    DISC-3405 is administered as a single dose IV infusion or subcutaneous injection

  • DISC-3405Drug

    DISC-3405 is administered in multiple ascending doses as an IV infusion or subcutaneous injection

  • PlaceboDrug

    Placebo is administered as a single dose IV infusion or subcutaneous injection

  • PlaceboDrug

    Placebo is administered in multiple ascending doses as an IV infusion or subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: up to 99 days
  2. Incidence of treatment-emergent clinically abnormal physical examTime frame: up to 99 days
  3. Incidence of treatment-emergent clinically significant laboratory test resultsTime frame: up to 99 days
  4. Incidence of treatment-emergent clinically significant electrocardiograms (ECGs)Time frame: up to 99 days
  5. Incidence of treatment-emergent clinically abnormal vital signsTime frame: up to 99 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.